Health ❯ Healthcare ❯ Chronic Diseases

Obesity

Weight Management Type 2 Diabetes Treatment Options Diabetes Comorbidities Management Strategies Obesity Management Public Health Weight Loss Treatments Economic Impact of Obesity

GLP-1 Drugs Linked to Better Breast Cancer Survival in Large EHR Study

The analysis of health records cannot show the drugs caused the gains.

Mouse Study Finds Semaglutide Directly Reprograms Liver Cells to Ease Disease Without Weight Loss

Study Finds Some Antibiotics Disrupt Gut Microbiome for Up to Eight Years

Biomea Fusion Reports Positive 52-Week Phase II Results for Icovamenib in Diabetes

Rio Sets March 18 Launch for Public Semaglutide Care as Supplier Price Survey Opens

Abbott to Commercialize Novo Nordisk’s Semaglutide in India Under Extensior Brand

Oral Semaglutide Cuts Serious Heart-Failure Events 22% in Type 2 Diabetes With Heart Failure

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

New Review Finds Rapid Weight Return After Stopping GLP-1 Weight-Loss Drugs

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Oxford BMJ Review Finds Rapid Weight Rebound After Stopping Modern Weight-Loss Drugs

FDA Approves First Oral Weight-Loss GLP-1: Wegovy Pill to Launch in January

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

Mexico Launches PRONAM to Standardize Care Across Public Health Services

Oral Semaglutide 25 mg Shows Larger Metabolic Gains With At Least 15% Weight Loss in OASIS-4

Amgen Raises Outlook on Q3 Beat as MariTide Milestones Approach

Innovent Says Mazdutide Tops Semaglutide in China Phase 3 Diabetes Trial

WHO Adds GLP-1 Drugs and Cancer Immunotherapies to Essential Medicines List

Munich Pharmacy Offers Walk-In Flu and COVID Shots Today Ahead of Oktoberfest

ESC Data Tie Wegovy and Mounjaro to Lower HFpEF Hospitalization and Death, With Novo Citing CV Edge for Wegovy